BIO to Redouble Efforts to Ensure Regulatory Decision-Making is "Grounded in Scientific and Medical Expertise"
April 22, 2023
April 22, 2023
WASHINGTON, April 22 (TNStalk) -- The Biotechnology Innovation Organization issued the following statement on April 21, 2023:
* * *
The Supreme Court ruled today that mifepristone will remain accessible during the appeals process of the April 7 Texas ruling that would have declared the Food and Drug Administration (FDA) approval of the drug invalid.
BIO interim President and CEO, Rachel King, made the following statement.
"Today's decisio . . .
* * *
The Supreme Court ruled today that mifepristone will remain accessible during the appeals process of the April 7 Texas ruling that would have declared the Food and Drug Administration (FDA) approval of the drug invalid.
BIO interim President and CEO, Rachel King, made the following statement.
"Today's decisio . . .